Benitec Biopharma Inc.
BNTC
$14.10
$0.322.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -74.32% | -22.12% | 1.81% | -2.12% | -11.19% |
| Total Depreciation and Amortization | 15.45% | 9.82% | 4.13% | -2.49% | -9.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,905.05% | 628.63% | 226.42% | 375.71% | 82.64% |
| Change in Net Operating Assets | -332.45% | 484.57% | -164.52% | -106.53% | 64.43% |
| Cash from Operations | -21.57% | 7.61% | -20.39% | -4.68% | -7.72% |
| Capital Expenditure | 89.94% | 90.00% | -19,000.00% | -17,800.00% | -17,800.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 89.94% | 90.00% | -19,000.00% | -17,800.00% | -17,800.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.70% | 167.02% | 167.02% | 109.60% | 313.55% |
| Repurchase of Common Stock | -23,156.41% | -23,156.41% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 60.64% | 1,280.00% | 1.15% | 1.21% | -215.25% |
| Cash from Financing | 3.61% | 286.34% | 184.71% | 121.23% | 324.78% |
| Foreign Exchange rate Adjustments | 712.50% | 811.11% | 655.56% | -231.82% | -101.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.12% | 1,078.90% | 489.17% | 350.46% | 3,154.16% |